| Project/Area Number |
06454421
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | KYOTO PREFECTURAL UNIVERSITY OF MEDICINE |
|---|
Principal Investigator |
UEDA Satoshi KYOTO PREFECTURAL UNIVERSITY OF MEDICINE,MEDICAL SCHOOL,PROFESSOR, 医学部, 教授 (40094411)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MORITA Noriyuki KYOTO PREFECTURAL UNIVERSITY OF MEDICINE,MEDICAL SCHOOL,ASSISTANT PROFESSOR, 医学部, 助手 (50239662)
KAWATA Mituhiro KYOTO PREFECTURAL UNIVERSITY OF MEDICINE,MEDICAL SCHOOL,PROFESSOR, 医学部, 教授 (60112512)
NAKAGAWA Yoshio KYOTO PREFECTURAL UNIVERSITY OF MEDICINE,MEDICAL SCHOOL,ASSISTANT PROFESSOR, 医学部, 講師 (00188913)
SUGAWA Noriaki KYOTO PREFECTURAL UNIVERSITY OF MEDICINE,MEDICAL SCHOOL,ASSISTANT PROFESSOR, 医学部, 助手 (50244596)
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Project Status |
Completed (Fiscal Year 1995)
|
| Budget Amount *help |
¥7,300,000 (Direct Cost: ¥7,300,000)
Fiscal Year 1995: ¥1,900,000 (Direct Cost: ¥1,900,000)
Fiscal Year 1994: ¥5,400,000 (Direct Cost: ¥5,400,000)
|
|---|
| Keywords | malignant glioma / EGFR antisense gene therapy / retro-virus / aberrant EGFR / malignant afioma / EGFR ontisense gene therapy / レトロウイルス / 異常EGFR / antisense gene therapy / EGFR / retrovirus |
|---|
| Research Abstract |
Epidermal growth factor receptor (EGFR) plays an important role in the progression of malignancy in gliomas. We studied the growth inhibition of the malignant glioma cell lines using an antisense EGFR oligonucleotide (normal phosphodister oligonucleotide) enveloped with Lipofectin^R (BRL) and we could have a good result. This time, we succeeded to develop the recombinant retro-virus vector expressiog EGFR antisense oligonucleotide, and we could inhibit the growth of the malignant glioma cell line using this retro-virus vector.
We analyzed structure of EGFR in 80 gliomas, and found that 40% of human malignant gliomas in vivo expressed aberrant EGFR.Furthermore, we have found two kinds of new aberrant EGFR.
|
